Recently, Sino Biopharmaceutical Limited (1177.HK) officially released the "Green Supply Chain Initiative", fully engaging with industry chain partners. It advocates for building a green and sustainable pharmaceutical industry chain through high-standard environmental governance and collaborative low-carbon actions, supporting the implementation of the national "dual carbon" strategy and leading a new paradigm for ESG development in the industry. 

As a benchmark enterprise for ESG construction in China's pharmaceutical industry, Sino Biopharmaceutical has taken the lead in the industry by releasing its "Carbon Neutrality Goals and Pathway Plan". This plan clarifies the long-term strategy of "achieving carbon neutrality in group operations by 2055 and in the value chain by 2060", continuously promoting the green transformation of itself and its industry chain. This initiative revolves around five core dimensions: environmental management systems, pollution prevention, energy conservation and carbon reduction, waste management, and ecological protection. It sets clear green operational standards for suppliers and is a significant measure for the company to deepen its ESG governance and fulfill its corporate responsibilities. The aim is to drive the entire industry chain to improve its environmental management level and promote the low-carbon upgrading of the pharmaceutical industry through unified standards and coordinated actions. 

The release of this "Green Supply Chain Initiative" represents Sino Biopharmaceutical Limited's determination and expectation to create a closed-loop green management system for the entire industry chain. The company will deeply integrate the content of the initiative into key processes such as supplier access, bidding and procurement, performance assessment, and tiered management. Through a supply chain ESG self-assessment system, it will regularly conduct audits and promotional training to promote the cascading transmission of green responsibility. 

On this basis, the company also collaborates with packaging material suppliers to co-create low-carbon technologies and promote environmental projects such as replacing materials with paper. While meeting drug packaging requirements, this has led to a 15% saving in packaging materials, achieving a win-win situation for both green initiatives and efficiency through technological innovation, and providing a practical example for collaborative carbon reduction in the industry chain. 

In recent years, the company's innovative practices in building a sustainable supply chain have received widespread recognition from international authoritative media, professional research institutions, and others. In 2025, Sino Biopharmaceutical won the "Ram Charan Management Practice Award - Corporate ESG Practice Award" for its "Sustainable Supply Chain Special Project", and was included as a typical case in the Harvard Business Review case library. This year, Sino Biopharmaceutical once again received the "Best Practice Case for Supply Chain Collaborative Innovation" award from the CSO Global Sustainability Forum. 

The green development of the pharmaceutical industry cannot be achieved without the concerted efforts of the entire industry chain. In the future, the company will continue to play a leading role in the industry. Using this initiative as a link, it will deepen green collaboration with upstream and downstream partners, share low-carbon technologies, jointly build green standards, and share environmental responsibilities. It aims to create a low-carbon, efficient, safe, and sustainable green pharmaceutical industry chain, contributing Sino Biopharmaceutical's strength to the high-quality development of the industry and the achievement of the national and company's 2060 carbon neutrality goals.